Marinus Nixes Ganaxolone Indication After Trial Fail
The biotech vows to continue development of the drug in pediatric indications after a late-stage failure in an adult seizure disorder.
You may also be interested in...
The biotech announces another poor performance for its lead drug candidate, but puts a positive spin on the data and plans continued development.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.